Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

VYNE Therapeutics (VYNE) Return on Invested Capital (2019 - 2025)

VYNE Therapeutics' Return on Invested Capital history spans 7 years, with the latest figure at 1.03% for Q2 2025.

  • For Q2 2025, Return on Invested Capital changed N/A year-over-year to 1.03%; the TTM value through Jun 2025 reached 1.03%, changed N/A, while the annual FY2025 figure was 0.75%, 13.0% down from the prior year.
  • Return on Invested Capital reached 1.03% in Q2 2025 per VYNE's latest filing, down from 0.94% in the prior quarter.
  • In the past five years, Return on Invested Capital ranged from a high of 0.54% in Q2 2021 to a low of 2.69% in Q1 2021.
  • Average Return on Invested Capital over 5 years is 1.12%, with a median of 0.94% recorded in 2025.
  • Peak YoY movement for Return on Invested Capital: skyrocketed 508bps in 2021, then tumbled -133bps in 2023.
  • A 5-year view of Return on Invested Capital shows it stood at 0.72% in 2021, then tumbled by -34bps to 0.96% in 2022, then tumbled by -120bps to 2.11% in 2023, then surged by 64bps to 0.75% in 2024, then tumbled by -36bps to 1.03% in 2025.
  • Per Business Quant, the three most recent readings for VYNE's Return on Invested Capital are 1.03% (Q2 2025), 0.94% (Q1 2025), and 0.75% (Q4 2024).